Interpace Biosciences, Inc. (IDXG)
IDXG Stock Price Chart
Explore Interpace Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze IDXG price movements and trends.
IDXG Company Profile
Discover essential business fundamentals and corporate details for Interpace Biosciences, Inc. (IDXG) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
20 May 1998
Employees
111.00
Website
https://www.interpace.comCEO
Thomas W. Burnell
Description
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
IDXG Financial Timeline
Browse a chronological timeline of Interpace Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 3 Nov 2025
Earnings released on 8 Aug 2025
EPS came in at -$0.12 , while revenue for the quarter reached $9.23M .
Earnings released on 8 May 2025
EPS came in at $0.06 , while revenue for the quarter reached $11.52M .
Earnings released on 31 Mar 2025
EPS came in at $0.66 , while revenue for the quarter reached $12.32M .
Earnings released on 4 Nov 2024
EPS came in at $0.31 , while revenue for the quarter reached $12.30M .
Earnings released on 2 Aug 2024
EPS came in at $0.48 , while revenue for the quarter reached $12.04M .
Earnings released on 9 May 2024
EPS came in at $0.13 , while revenue for the quarter reached $10.27M .
Earnings released on 1 Apr 2024
EPS came in at -$3.35 falling short of the estimated -$0.25 by -1.24K%, while revenue for the quarter reached $10.28M , missing expectations by -91.55%.
Earnings released on 8 Nov 2023
EPS came in at -$0.12 falling short of the estimated -$0.01 by -1.10K%, while revenue for the quarter reached $9.08M , beating expectations by +8.95%.
Earnings released on 9 Aug 2023
EPS came in at $0.09 surpassing the estimated -$0.08 by +212.50%, while revenue for the quarter reached $11.03M , beating expectations by +32.33%.
Earnings released on 12 May 2023
EPS came in at $0.10 surpassing the estimated -$0.19 by +152.63%, while revenue for the quarter reached $9.83M , beating expectations by +17.93%.
Earnings released on 27 Mar 2023
EPS came in at -$0.33 falling short of the estimated -$0.07 by -371.43%, while revenue for the quarter reached $8.33M , missing expectations by -38.28%.
Earnings released on 14 Nov 2022
EPS came in at -$0.30 falling short of the estimated -$0.25 by -20.00%, while revenue for the quarter reached $8.19M , missing expectations by -34.49%.
Earnings released on 15 Aug 2022
EPS came in at -$0.92 falling short of the estimated -$0.52 by -76.92%, while revenue for the quarter reached $9.35M , missing expectations by -10.94%.
Earnings released on 16 May 2022
EPS came in at -$0.52 surpassing the estimated -$0.80 by +35.00%, while revenue for the quarter reached $10.38M , beating expectations by +15.30%.
Earnings released on 31 Mar 2022
EPS came in at -$0.90 falling short of the estimated -$0.32 by -181.25%, while revenue for the quarter reached $10.85M , missing expectations by -5.63%.
Earnings released on 10 Nov 2021
EPS came in at -$0.85 falling short of the estimated -$0.62 by -37.10%, while revenue for the quarter reached $9.47M , missing expectations by -17.63%.
Earnings released on 10 Aug 2021
EPS came in at -$0.90 surpassing the estimated -$1.01 by +10.89%, while revenue for the quarter reached $11.16M .
Earnings released on 11 May 2021
EPS came in at -$1.02 surpassing the estimated -$1.43 by +28.67%, while revenue for the quarter reached $9.83M , missing expectations by -21.86%.
Earnings released on 31 Mar 2021
EPS came in at -$2.00 falling short of the estimated -$1.32 by -51.52%, while revenue for the quarter reached $9.65M .
Earnings released on 20 Jan 2021
EPS came in at -$1.53 , while revenue for the quarter reached $8.25M .
Earnings released on 19 Oct 2020
EPS came in at -$1.35 surpassing the estimated -$1.48 by +8.78%, while revenue for the quarter reached $5.45M , missing expectations by -8.09%.
IDXG Stock Performance
Access detailed IDXG performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.